September 2026

Macquarie Subordinated Debt Fund (ASX:MQS) reported a sharp increase in operating profit and assets for the year ended 30 June 2026, powered by the expansion of its active ETF class. The audited accounts also show the fund’s returns remain closely exposed to interest rates, credit spreads and debt-market valuations.

Macquarie Core Australian Equity Active ETF more than doubled its net assets to $1.138 billion in the year to 30 June 2026, powered by $676.067 million of new applications. Profit rose 50% to $33.876 million, while distributions increased to 30.93 cents per unit.

Walter Scott Global Equity Fund’s operating profit fell to A$4.1 million in 2026 from A$349.5 million, while net assets dropped by about A$1.1 billion. The audited report points to weaker investment gains and substantial redemptions, although the fund remained fully invested in quoted equities and received an unmodified audit opinion.

Macquarie Income Opportunities Fund reported a sharp decline in operating profit for 2026 as fair-value gains weakened, despite growth in net assets and distributions. The audited fund ended the year with A$3.033 billion attributable to unitholders and an unqualified audit opinion.

Macquarie Core Global Equity Fund (ASX:MQE) reported a sharp rise in FY2026 operating profit as net assets more than tripled and the portfolio expanded. The result reflects both substantial new applications and investment gains, rather than investment performance alone.

Pengana International Equities has cancelled 151.1 million shares in a $183.28 million buy-back, leaving a much smaller listed investment company and three fewer directors. The reconstituted board will review capital options before deciding whether to pursue a future rights issue.

Benjamin Hornigold Limited (ASX:BHD) delivered a 9.93% portfolio return in FY2026 but still posted a $420,931 loss after $565,697 in legal fees. Two settlements worth $2.6 million were received after year-end, while an $8.97 million judgment against JB Markets was assigned no value.

Imagion Biosystems has secured central ethics approval for its US Phase 1b/2 trial of the MagSense HER2 imaging agent, removing a key requirement before recruitment can begin. Site activation is now underway, but no patient has yet been enrolled and the announcement provides no clinical data.

Emperor Energy has secured NOPSEMA approval for the Judith-2 appraisal well, removing a major regulatory barrier ahead of targeted drilling in April 2027. The well will test a 166 Bcf contingent gas resource and investigate deeper prospective sands, although commercial conversion remains unproven.

Atlas Arteria has warned that France may more than double the tax rate applied to eligible toll-road operators, with APRR’s 2025 TEILD bill already reaching €126.7 million. The proposed changes remain subject to parliamentary debate and could be softened before becoming law.

Mayne Pharma has settled patent litigation with Sun Pharma over IMVEXXY, establishing 21 October 2032 as the agreed potential generic entry date, subject to court approval. The settlement involves no upfront payment, while one further Paragraph IV dispute remains unresolved.

Paradigm Biopharmaceuticals has entered voluntary administration after its pivotal Phase 3 trial produced an interim efficacy result below the threshold required for continuation. The company’s securities will remain suspended while administrators assess its viability, liabilities and possible restructuring options.

Silver Mines has built a substantially larger economic case for Bowdens, but the project still needs NSW approval before its 93.5 million ounce reserve can become a mine. The company is now funding the next phase with a A$70 million placement while absorbing dilution and a major royalty buy-back.

Papyrus Australia has produced a second batch of TBS board samples, expanded pulp capacity in Adelaide and secured additional funding as it moves towards commercial supply. The progress comes with testing still incomplete and an estimated 4.87 months of funding available.

Larvotto Resources has extended high-grade antimony-gold-tungsten mineralisation at Clarks Gully about 100 metres beyond its 2025 resource model, with drilling also identifying several hanging-wall lodes. The results could support a larger resource and a potential underground feed source for Hillgrove, but assays, modelling and permitting work remain outstanding.

Felix Gold advanced bulk extraction, processing and refinery plans at its Alaska antimony project in FY26, but the push came with a larger loss, falling cash and an auditor-documented material uncertainty over going concern. A potential US$18 million Department of Energy award remains subject to negotiation rather than a committed funding source.

Accelerate Resources enters FY2027 with high-grade manganese targets at Woodie Woodie North and new gold zones at Balagundi, but a sharp annual loss and ongoing funding needs remain part of the story. The company plans maiden and follow-up drilling while seeking shareholder approval to rename itself Mango Metals.

6K Additive has signed a 30-month Nickel 718 powder supply agreement with US advanced manufacturer ADDMAN, carrying a stated value of up to US$10.8 million. The deal also introduces a buy-back arrangement for used powder, linking new sales with recycled feedstock.

AnteoTech has set sales conversion as its FY2027 priority after FY2026 sales revenue slipped to A$460,397, while operating expenses fell sharply and cash stood at A$11.2 million. The battery materials and life sciences company says customer evaluations and partnership discussions are building, but most opportunities remain short of recurring commercial revenue.

Brazilian Rare Earths has identified a new high-grade rare earth system at Sulista South, with mineralisation traced across about 500 metres and grades reaching 13.3% TREO. Step-out and infill drilling at Sulista East has also extended the known footprint and strengthened the case for a larger year-end resource estimate.

Vectus Biosystems has secured a pre-IND Type B meeting with the FDA for its lead IPF drug candidate VB0004. The regulator’s written feedback, expected by mid-November, should clarify the next US development steps but does not yet authorise clinical trials.

Forrestania Resources has lifted the higher-confidence portion of its Lady Ada and Lady Magdalene gold resource by 43%, even as total contained ounces fall 4% to 285,700 ounces. The update strengthens the development case, but most of the resource remains Inferred and the tenements are subject to ongoing legal proceedings.

PDI Gold’s first full annual report after its Robex merger shows a transformed West African gold business with US$193.7 million in cash and two producing mines. The statutory result remains a US$63.7 million loss, while Bankan’s next phase still depends on an exploitation permit from Guinea.

Alcidion will roll out its Miya Flow software across four Northern Care Alliance hospitals under a new A$7.5 million contract. About A$4.5 million is expected to be recognised as revenue in the current year, including a six-month renewal of the existing ExtraMed system during implementation.